Cell and Gene Therapy Access Challenges

In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies.  Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI HealthEric Faulkner, President, Passage Health AssociatesADVI HealthAlliance for Regenerative MedicineARPA-HBespoke Gene Therapy ConsortiumBlue Bird BioBlue Cross Blue ShieldMedicare DRG RatesNICE (National Institute for Health and Care Excellence)NovartisPassage Health AssociatesREMS ProgramSingle Case AgreementsSpark Therapeutics Medical terminology referenced in this episode: Alzheimer's Aspheresis CAR T therapy Hemophilia Hepatitus C Luxturna Metachromatic leukodystrophy  Myeloablative Conditioning Sickle Cell Disease SMA treatment Spinraza Vaso Occlusive Crises Zolgensma